Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





CT Scan Study Shows Evidence of Persistent Lung Damage Long After COVID-19 Pneumonia

By HospiMedica International staff writers
Posted on 01 Apr 2022

The COVID-19 pandemic, caused by the novel severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has considerably increased the demand for acute and post-acute healthcare worldwide. More...

COVID-19’s short-term effects on the lungs, such as pneumonia, are well documented. Much less is known about the illness’ long-term effects on the lungs. CT has been an important imaging tool in the workup of patients suspected of having COVID-19. Now, a new study has found that some people recovering from COVID-19 pneumonia have CT evidence of damage to their lungs that persists a full year after the onset of symptoms. The study underscores radiology’s role in helping identify patients at risk for post-COVID-19 consequences and assisting in COVID-19 follow-up management.

As part of an observational study on the development of lung disease in patients with SARS-CoV-2 infection, researchers at Innsbruck Medical University (Innsbruck, Austria) looked at patterns and rates of improvement of chest CT abnormalities in patients one year after COVID-19 pneumonia. The researchers assessed lung abnormalities on chest CT in 91 participants, mean age 59 years, at several points over one year after the onset of COVID-19 symptoms.

At one year, CT abnormalities were present in 49, or 54%, of the 91 participants. Of these 49 participants, two (4%) had received outpatient treatment only, while 25 (51%) were treated on a general hospital ward and 22 (45%) had received intensive care unit (ICU) treatment. While CT abnormalities decreased in initial follow-ups, 63% of participants with abnormalities did not show any further improvement after six months. Age over 60 years, critical COVID-19 severity and male gender were associated with persistent CT abnormalities at one year. Evidence from the SARS-CoV-1 outbreak of 2002 to 2004 shows that lung abnormalities may remain detectable even after decades, but do not show any progression, according to the researchers. Recent studies, though, have shown a risk of progression of lung abnormalities such as the ones depicted on CT. The researchers intend to continue gathering data on patients with persistent CT abnormalities

“The observed chest CT abnormalities from our study are indicative of damaged lung tissue,” said study co-author Anna Luger, M.D., from the Department of Radiology at Innsbruck Medical University in Innsbruck, Austria. “However, it is currently unclear if they represent persistent scarring, and whether they regress over time or lead to pulmonary fibrosis.”

“In a recently published clinical study of our CovILD interdisciplinary working group, we were able to show that the severity of acute COVID-19, protracted systemic inflammation and the presence of residual chest CT abnormalities are strongly related to persistently impaired lung function and clinical symptoms,” said study co-author Christoph Schwabl, M.D., from Innsbruck Medical University.

“In the end, long-term follow-up, both clinical and radiological, is necessary to gather more information about the course and clinical role of persisting SARS-CoV-2 related chest CT abnormalities,” said study senior author Gerlig Widmann, M.D., chief thoracic radiologist at Innsbruck Medical University.

Related Links:
Innsbruck Medical University 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.